Shopping Cart
clear

Request a Demo or a Quote

Your contact information:
Product Information:

Cytek Biosciences Supports COVID-19 Research Through Instrument Contributions, Continuing Operations and Customer Support


FREMONT, Calif., March 19, 2020 - Cytek Biosciences Inc. is committed to supporting researchers and clinicians around the world who are studying the impact of the COVID-19 virus on human immune systems.  The Cytek family operates to ensure that everyone researching COVID-19 with the Cytek Aurora, Cytek Athena, and Cytek Northern Lights systems remains fully supported during this crucial period and can quickly obtain technical assistance from our team of experts when needed.

To further accelerate this critically important work, Cytek has contributed several instruments to leading clinical laboratories in China for use in COVID-19 clinical research and diagnostic test development. We attained clinical use certification in China in 2019 for our DxPTM Athena and Northern Lights CLC instruments, which has enabled us to support a growing list of clinical research institutions, including a hospital in the center of the pandemics in Wuhan.

Cytek greatly appreciates the efforts of all researchers and healthcare workers globally that continue to help people combat viruses like COVID-19 through immune monitoring, biomarker identification, and vaccine development. Through these collaborations and future ones to come, the Cytek family envisions our products positively impacting human health in COVID-19 and other human diseases.

About Cytek Biosciences, Inc.

Cytek Biosciences Inc. is a leading flow cytometry solution provider that develops compact, affordable instruments with high multiplexing capability and a wide range of services to support scientists and clinicians. Cytek is headquartered in Fremont, California with branch offices and distribution channels across the globe. More information about the company and its products is available at www.cytekbio.com. To learn more, follow Cytek on LinkedIn, Twitter and Facebook.